PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses...

C4X Discovery Holdings Limited announces progress on immuno-inflammation programmes and appointment of new Board members C4X Discovery Holdings Limited C4XD announces progress on immuno-inflammation programmes and appointment of new Board members 22 July 2024 - C4X Discovery Limited (“C4XD”), a pioneering drug...